Interleukin gets retinopathy risk test patent:
This article was originally published in Clinica
Interleukin Genetics has gained a US patent covering a genetic test for identifying diabetics who are at increased risk for developing sight-threatening retinopathy. The patent is based on the discovery that diabetics carrying certain common variations in the IL-1 genes are more likely to develop the disease and lose their sight. By identifying which people are on a more rapid path to complications, patient-monitoring schedules may be adjusted and additional preventive measures may be applied to reduce the likelihood of serious complications, said the Waltham, Massachusetts firm. Each year, around 20,000-30,000 people lose their sight due to diabetic retinopathy, the company added.